Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Receptos Inc.

Division of Celgene Corp.
receptos.com

Latest From Receptos Inc.

Celgene's Positive Ozanimod Data Puts Focus On MS Commercialization

A second Phase III multiple sclerosis trial testing the S1P1 modulator was positive, turning attention to whether or not Celgene will market the drug independently for the indication and how the drug might be positioned against an eventual generic Gilenya.

Research & Development Neurology

Safety Is Key As Celgene's Ozanimod Succeeds In First Pivotal MS Test

Celgene's ozanimod successfully cleared its first Phase III hurdle in multiple sclerosis, but safety will be the S1P receptor modulator's differentiating factor in results presented later this year, with additional value coming from ulcerative colitis and Crohn's disease in the coming years.

Research & Development Clinical Trials

M&A Analysis Reveals Mid Pharma Purchase Preferences

Immunology- and inflammation-focused biotech companies wondering if a trade exit is in their future will be interested to read that, according to a report from Datamonitor Healthcare, their demographic is the most popular acquisition target of the mid-size pharma cohort.

Commercial Deals

Billions On The Line With Celgene’s Partnered Pipeline

Celgene’s fourth quarter and 2016 sales aligned with previously disclosed double-digit gains as the company outlined later-stage pipeline programs expected to add billions in sales during the next five years.

Commercial Sales & Earnings
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Gastrointestinal
  • Immune Disorders
  • Metabolic Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Receptor Pharmaceuticals Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Celgene Corp.
  • Senior Management
  • Faheem Hasnain, Pres. & CEO
    Graham Cooper, CFO
    Chrysa Mineo, SVP, Corp. Dev.
    Shelia Gujrathi, MD, CMO
    Robert J Peach, PhD, CSO
    Marcus T Boehm, PhD, CTO
  • Contact Info
  • Receptos Inc.
    Phone: (858) 652-5700
    3033 Science Park Rd.
    Ste. 300
    San Diego, CA 92121
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register